Inactive Instrument

Cempra Inc Stock Nasdaq

US15130J1097

Biotechnology & Medical Research

Melinta Therapeutics Inc is a United States-based commercial-stage antibiotics company. The Company's products include Vabomere, Orbactiv, Minocin for injection, and Baxdela. Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Vabomere is indicated for the treatment of patients over 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs). Minocin for injection is indicated for the treatment of infections due to susceptible isolates of designated microorganisms, including Acinetobacter species bacteria.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

25-09-02	CorMedix Inc. Announces Executive Changes, Effective August 29, 2025	CI
25-08-28	CorMedix Inc. completed the acquisition of Melinta Therapeutics, LLC from Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., funds managed by Deerfield Management Company, L.P. and other equity shareholders for approximately $330 million.	CI
25-08-07	CorMedix Inc. entered into a definitive agreement to acquire Melinta Therapeutics, LLC from Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., funds managed by Deerfield Management Company, L.P. and other equity shareholders for approximately $330 million.	CI
24-05-23	Melinta Therapeutics, LLC Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 Trial and Recently Approved Rezafungin CLSI Breakpoints for Candida Glabrata and Candida Auris	CI
24-02-23	Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	CI
24-02-20	New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	CI
23-12-05	Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	CI
23-10-02	Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	CI
23-07-10	Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	CI
23-03-22	Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	CI
23-01-25	Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	CI
22-11-28	Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	CI
22-04-06	Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	CI

Manager	Title	Age	Since
Christine Ann Miller CEO	Chief Executive Officer	50	2020-08-02
Fabrizio Tondolo CTO	Chief Tech/Sci/R&D Officer	-	-
Sunitha Lakshminarayanan CTO	Chief Tech/Sci/R&D Officer	-	2024-08-31

Director	Title	Age	Since
Sumner Esten Anderson BRD	Director/Board Member	-	2020-04-19
Bryan B. Sendrowski BRD	Director/Board Member	-	2020-04-19
Jonathan Leff BRD	Director/Board Member	57	2020-04-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEMPRA INC	-5.53%	+13.71%	-	-	893K
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	-3.05%	-2.62%	+40.54%	+184.05%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+39.55%	+143.13%

Cempra Inc Stock Nasdaq

Stocks

US15130J1097

Biotechnology & Medical Research

Latest news : Cempra Inc

Quotes and Performance

Managers and Directors: Cempra Inc

Bio Therapeutic Drugs

Company Profile